Norge - norsk - Statens legemiddelverk

medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 5 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 7.5 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 10 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - schizofreni - psykoleptiske - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Den europeiske union - norsk - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuskulær blokkade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Norge - norsk - Statens legemiddelverk

navamedic asa - klindamycinfosfat - injeksjonsvæske/konsentrat til infusjonsvæske, oppløsning - 150 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Den europeiske union - norsk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukemi, myeloid, akutt - antineoplastiske midler - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Norge - norsk - Statens legemiddelverk

cis bio international - natriumjodid (131 i) - kapsel, hard - 50 mbq

Norge - norsk - Statens legemiddelverk

curium netherlands b.v. - natriumjodid (131i) - kapsel, hard